Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (11-20 of 158) with videos related to

Pageof 16
Sort By:
Breast (Edinburgh, Scotland)|September 10, 2013
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancerXiaoyong Fu, C Kent Osborne, Rachel Schiff
Lancet (London, England)|January 17, 2004
Spreading the word, but not too thinlyAnthony Howell, C Kent Osborne, Louis Mauriac
Transactions of the American Clinical and Climatological Association|July 18, 2020
DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCERC Kent Osborne, Rachel Schiff, Mothamar Rimawi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Aromatase inhibitor adverse effects: are we sweeping them under the rug?Polly Niravath, Mothaffar F Rimawi, C Kent Osborne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2011
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patientStefan Glück, Carlos L Arteaga, C Kent Osborne
Annual Review of Medicine|January 15, 2015
Targeting HER2 for the treatment of breast cancerMothaffar F Rimawi, Rachel Schiff, C Kent Osborne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate responseRachel Schiff, Suleiman Massarweh, Jiang Shou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancerC Kent Osborne, Jiang Shou, Suleiman Massarweh, et al.
Endocrine Reviews|January 25, 2008
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistanceGrazia Arpino, Lisa Wiechmann, C Kent Osborne, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Biological mechanisms and clinical implications of endocrine resistance in breast cancerMario Giuliano, Rachel Schifp, C Kent Osborne, et al.
Pageof 16

Showing results (11-20 of 158) with videos related to

Sort By:
Pageof 16
Breast (Edinburgh, Scotland)|September 10, 2013
Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancerXiaoyong Fu, C Kent Osborne, Rachel Schiff
Lancet (London, England)|January 17, 2004
Spreading the word, but not too thinlyAnthony Howell, C Kent Osborne, Louis Mauriac
Transactions of the American Clinical and Climatological Association|July 18, 2020
DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCERC Kent Osborne, Rachel Schiff, Mothamar Rimawi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
Aromatase inhibitor adverse effects: are we sweeping them under the rug?Polly Niravath, Mothaffar F Rimawi, C Kent Osborne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2011
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patientStefan Glück, Carlos L Arteaga, C Kent Osborne
Annual Review of Medicine|January 15, 2015
Targeting HER2 for the treatment of breast cancerMothaffar F Rimawi, Rachel Schiff, C Kent Osborne
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate responseRachel Schiff, Suleiman Massarweh, Jiang Shou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancerC Kent Osborne, Jiang Shou, Suleiman Massarweh, et al.
Endocrine Reviews|January 25, 2008
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistanceGrazia Arpino, Lisa Wiechmann, C Kent Osborne, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Biological mechanisms and clinical implications of endocrine resistance in breast cancerMario Giuliano, Rachel Schifp, C Kent Osborne, et al.
Pageof 16